Geneva, Oct. 27 -- International Clinical Trials Registry received information related to the study (ChiCTR2600134611) titled 'Efficacy, Safety and Cardioprotective Effects of Mazdutide in Type 1 Diabetes Mellitus' on Oct. 16.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: Peking University People's Hospital
Condition:
Type 1 diabetes
Intervention:
Trial group:Receive Mazidutide, subcutaneous injection once weekly. Dose will be gradually increased according to a predefined protocol from the safety starting dose to the effective maintenance dose (from 2mg to 4mg), lasting for several weeks, and reduction is allowed if necessary
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 20...